[go: up one dir, main page]

MX2009006755A - Celulas y metodologia para generar virus de rna de cadena de sentido negativo no segmentada. - Google Patents

Celulas y metodologia para generar virus de rna de cadena de sentido negativo no segmentada.

Info

Publication number
MX2009006755A
MX2009006755A MX2009006755A MX2009006755A MX2009006755A MX 2009006755 A MX2009006755 A MX 2009006755A MX 2009006755 A MX2009006755 A MX 2009006755A MX 2009006755 A MX2009006755 A MX 2009006755A MX 2009006755 A MX2009006755 A MX 2009006755A
Authority
MX
Mexico
Prior art keywords
cells
rna viruses
segmented negative
methodology
measles
Prior art date
Application number
MX2009006755A
Other languages
English (en)
Inventor
Pierre Charneau
Frederic Tangy
Yves Jacob
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of MX2009006755A publication Critical patent/MX2009006755A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a células recombinantes así como métodos para la generación de virus de RNA de cadena sencilla de sentido negativo no segmentada (NNV o mononegavirales) de ácido deoxiribonucleico clonado (ADNc), especialmente de virus de sarampión y en forma particular cepas atenuadas tales como las aprobadas para la vacunación, en forma particular de virus de sarampión atenuado Schwarz y varios virus recombinantes con base en sarampión Schwarz que expresan las secuencias heterólogas. Estos virus rescatados pueden utilizarse, después de la amplificación, como vacunas para inmunización en contra de sarampión y/o en contra de péptidos heterólogos o proteínas expresadas.
MX2009006755A 2006-12-22 2007-12-21 Celulas y metodologia para generar virus de rna de cadena de sentido negativo no segmentada. MX2009006755A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06292025.1A EP1939214B1 (en) 2006-12-22 2006-12-22 Cells and methodology to generate non-segmented negative-strand RNA viruses
PCT/IB2007/004444 WO2008078198A2 (en) 2006-12-22 2007-12-21 Cells and methodology to generate non-segmented negative-strand rna viruses

Publications (1)

Publication Number Publication Date
MX2009006755A true MX2009006755A (es) 2009-07-31

Family

ID=37831098

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006755A MX2009006755A (es) 2006-12-22 2007-12-21 Celulas y metodologia para generar virus de rna de cadena de sentido negativo no segmentada.

Country Status (11)

Country Link
US (2) US8586364B2 (es)
EP (2) EP1939214B1 (es)
JP (2) JP5902371B2 (es)
KR (1) KR101469007B1 (es)
CN (2) CN104745533A (es)
BR (1) BRPI0719469C1 (es)
CA (1) CA2673262C (es)
DK (2) DK1939214T3 (es)
ES (2) ES2423518T3 (es)
MX (1) MX2009006755A (es)
WO (1) WO2008078198A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1375670B1 (en) 2002-06-20 2013-06-12 Institut Pasteur Recombinant measles viruses expressing epitopes of antigens of RNA viruses and use of the recombinant viruses for the preparation of vaccine compositions
EP1375512B1 (en) 2002-06-20 2009-07-22 Institut Pasteur Infectious cDNA of an approved vaccine strain of measles virus. Use for immunogenic compositions
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
WO2012038832A2 (en) * 2010-09-24 2012-03-29 Institut Pasteur Generation of replicating chimeric measles virus - retrovirus particles
CN103906843B (zh) * 2011-06-08 2016-12-07 维什瓦斯·乔希 双质粒哺乳动物表达系统
FR2994697B1 (fr) * 2012-08-24 2016-05-13 Centre De Coop Int En Rech Agronomique Pour Le Dev (Cirad) Souche vaccinale marquee du virus de la peste des petits ruminants, et son procede d'obtention
EP2712871A1 (en) 2012-09-27 2014-04-02 Institut Pasteur Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications
EP2759301A1 (en) 2013-01-24 2014-07-30 Institut Pasteur Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus)
US20140255447A1 (en) * 2013-03-05 2014-09-11 Biomune Company Production of avian embryo cells
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
WO2016110869A2 (en) 2015-01-05 2016-07-14 Joshi Vishwas Dattatraya Dna molecules producing custom designed replicating and non-replicating negative stranded rna viruses and uses there of
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
EP3255056A1 (en) * 2016-06-06 2017-12-13 Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives Method for producing self-assemblying paramyxoviral nucleocapsid-like particles and their uses
WO2018206512A1 (en) 2017-05-09 2018-11-15 Invectys Recombinant measles vaccine expressing htert
EP3412307A1 (en) 2017-06-07 2018-12-12 Institut Pasteur Recombinant measles virus expressing zika virus proteins and their applications
CN107557340A (zh) * 2017-09-26 2018-01-09 南京普菲科医药科技有限公司 一种可诱导性拯救弹状病毒的细胞系及其构建方法与应用
EP3707154A1 (en) 2017-11-09 2020-09-16 Institut Pasteur A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition
MX2020006476A (es) 2017-12-21 2020-12-10 Pasteur Institut Vacuna contra el virus de lassa.
EP3820884A1 (en) * 2018-07-13 2021-05-19 Valneva SE Method for rescuing and producing a virus in avian cells
CN109355301A (zh) * 2018-08-22 2019-02-19 深圳大学 一种石斑鱼重组NNVcp的密码子优化的核酸序列、融合表达载体、制备方法及其本身
CN111218474A (zh) * 2018-11-23 2020-06-02 成都生物制品研究所有限责任公司 一种副粘病毒的拯救系统和副粘病毒拯救方法
EP3673917A1 (en) 2018-12-28 2020-07-01 Themis Bioscience GmbH Norovirus vaccines
CN109913423A (zh) * 2019-03-27 2019-06-21 扬州大学 一种稳定表达猪德尔塔冠状病毒N蛋白的重组Vero细胞系及应用
MX2022009989A (es) 2020-02-13 2022-11-08 Pasteur Institut Composiciones inmunogenicas y vacunas para covid-19 vectorizadas por sarampion.
EP3865180A1 (en) 2020-02-13 2021-08-18 Institut Pasteur Live recombinant measles virus expressing coronavirus antigens - its use in eliciting immunity against coronaviruses
WO2021222228A1 (en) * 2020-04-27 2021-11-04 Ohio State Innovation Foundation A live attenuated measles virus vectored vaccine for sars-cov-2
EP3936517A1 (en) * 2020-07-08 2022-01-12 Institut Pasteur An improved measles virus vaccine vector based on multiple tandem additional transcription units
WO2022152818A1 (en) 2021-01-13 2022-07-21 Viroxis Measles-hiv or measles-htlv vaccine
WO2023230598A2 (en) * 2022-05-27 2023-11-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Reverse genetics system for feline morbillivirus
EP4501946A1 (en) 2023-07-31 2025-02-05 LoopLab Bio GmbH Self-amplifying biologics for targeted therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0780475B2 (en) * 1995-08-09 2006-07-19 SCHWEIZ. SERUM- & IMPFINSTITUT BERN Process for the production of infectious negative-strand RNA viruses
PT1224314E (pt) 1999-10-12 2007-04-30 Pasteur Institut Adn triplex lentiviral e vectores e células recombinantes contendo adn triplex lentiviral.
WO2001096376A2 (en) 2000-06-16 2001-12-20 Institut Pasteur Pro-apoptotic fragments of the dengue virus envelope glycoproteins
EP1375670B1 (en) 2002-06-20 2013-06-12 Institut Pasteur Recombinant measles viruses expressing epitopes of antigens of RNA viruses and use of the recombinant viruses for the preparation of vaccine compositions
DE10234579A1 (de) * 2002-07-30 2004-02-12 Zf Friedrichshafen Ag Getriebe
CA2528002A1 (en) * 2003-06-09 2004-12-29 Wyeth Improved method for the recovery of non-segmented, negative-stranded rna viruses from cdna
JP5054384B2 (ja) 2003-12-02 2012-10-24 インスティティ・パスツール Ｓａｒｓ関連コロナウイルスの新規系統及びその利用
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
CA2604242A1 (en) * 2005-04-14 2006-10-19 The University Of Queensland Immunomodulating compositions and uses therefor

Also Published As

Publication number Publication date
CA2673262C (en) 2019-03-05
CN104745533A (zh) 2015-07-01
EP2091962B1 (en) 2018-07-04
CN101631798A (zh) 2010-01-20
US20100144040A1 (en) 2010-06-10
BRPI0719469B1 (pt) 2019-07-02
ES2423518T3 (es) 2013-09-20
JP2010512779A (ja) 2010-04-30
BRPI0719469A2 (pt) 2014-02-11
EP1939214B1 (en) 2013-07-10
DK2091962T3 (en) 2018-10-08
WO2008078198A2 (en) 2008-07-03
US20140051148A1 (en) 2014-02-20
US8586364B2 (en) 2013-11-19
JP5902371B2 (ja) 2016-04-13
WO2008078198A3 (en) 2008-10-30
EP2091962A2 (en) 2009-08-26
EP1939214A1 (en) 2008-07-02
ES2686168T3 (es) 2018-10-16
BRPI0719469C1 (pt) 2021-05-25
DK1939214T3 (da) 2013-10-14
KR101469007B1 (ko) 2014-12-05
KR20090103922A (ko) 2009-10-01
US9499799B2 (en) 2016-11-22
JP2015015955A (ja) 2015-01-29
CA2673262A1 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
MX2009006755A (es) Celulas y metodologia para generar virus de rna de cadena de sentido negativo no segmentada.
Meyer et al. Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses
CY1119284T1 (el) ΣΩΜΑΤΙΔΙΑ ΠΑΡΟΜΟΙΑ ΜΕ ΙΟ ΓΛΥΚΟ-ΠΡΩΤΕΪΝΗΣ ΛΥΣΣΑΣ (VLPs)
MX2013008836A (es) Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.
IN2012DN00650A (es)
MX345700B (es) Proteinas f del vrs modificadas y metodos de uso de las mismas.
EP1917033A4 (en) VIRUS LIKE PARTICLES AS PARAMYXOVIRUS VACCINES
MX358725B (es) Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
WO2009105152A3 (en) Virus-like particles as vaccines for paramyxovirus
CA3238757A1 (en) Coronavirus vaccine
WO2007002008A3 (en) Methods and compositions for expressing negative-sense viral rna in canine cells
WO2010039224A3 (en) Respiratory syncytial virus (rsv) sequences for protein expression and vaccines
MY161965A (en) New influenza virus immunizing epitope
WO2007124327A3 (en) Methods and compositions for expressing negative-sense viral rna in canine cells
MX2012012681A (es) Secuencias del virus de dengue universales y metodos de uso.
WO2011082388A3 (en) Infectious dna vaccines against chikungunya virus
WO2011034953A3 (en) Lassa virus-like particles and methods of production thereof
PH12020551152A1 (en) Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
PH12016502554A1 (en) A dengue virus chimeric polyepitope composed of fragments of non structural proteins and its use in an immunogenic composition against dengue virus infection
IN2015DN02546A (es)
MX375778B (es) Variantes mejoradas de enzimas.
WO2012047679A3 (en) Consensus antigen constructs and vaccines made there form, and methods of using same to treat malaria
MX2024006240A (es) Vacunas contra el metapneumovirus humano.
HK1212708A1 (zh) H1n1流感的計算優化的寬反應性抗原
ZA202003070B (en) Lassa vaccine

Legal Events

Date Code Title Description
FG Grant or registration